Abstract
We conducted a phase I clinical trial of an experimental live attenuated recombinant human metapneumovirus (HMPV) vaccine (rHMPV-Pa) sequentially in adults, HMPV-seropositive children, and HMPV-seronegative children, the target population for vaccination. rHMPV-Pa was appropriately restricted in replication in adults and HMPV-seropositive children but was overattenuated for HMPV-seronegative children.
Publication types
-
Clinical Trial, Phase I
-
Randomized Controlled Trial
MeSH terms
-
Adult
-
Antibodies, Viral / immunology
-
Child, Preschool
-
Double-Blind Method
-
Humans
-
Infant
-
Metapneumovirus / immunology*
-
Paramyxoviridae Infections / prevention & control*
-
Paramyxoviridae Infections / therapy
-
Vaccines, Attenuated / immunology
-
Vaccines, Attenuated / therapeutic use
-
Vaccines, Synthetic / immunology
-
Vaccines, Synthetic / therapeutic use
-
Viral Vaccines / immunology
-
Viral Vaccines / therapeutic use*
Substances
-
Antibodies, Viral
-
Vaccines, Attenuated
-
Vaccines, Synthetic
-
Viral Vaccines